14813-29-7

Usage

InChI:InChI=1/C27H22O14/c1-11(28)35-18-9-19(36-12(2)29)23-20(10-18)41-25(27(24(23)34)40-16(6)33)17-7-21(37-13(3)30)26(39-15(5)32)22(8-17)38-14(4)31/h7-10H,1-6H3

Upstream product

• 529-44-2 myricetin 
• 127-09-3 sodium acetate 
• 108-24-7 acetic anhydride 

Relevant academic research and scientific papers

FLAVONOL GLYCOSIDES FROM CALLITRIS GLAUCA

From the leaves of Callitris glauca myricetin 7-arabinoside, quercitrin, kaempferol 5-rhamnoside, a quercetin arabinoside, quercetin, kaempferol, galangin and shikimic acid were isolated.The natural occurrence of myricetin 7-arabinoside has not previously

ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE

Disclosed herein are acylated active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or non

ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE

Disclosed herein are acylated active agents (e.g., acylated hydroxybenzoic acid), compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for

ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER

Disclosed herein are acylated active agents and methods of their use, e.g., for modulating a cancer marker or for treating cancer.

ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE

Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS

Disclosed herein are acylated active agents (e.g., acylated catechin polyphenols, acylated carotenoids, acylated mesalamines, acylated sugars, acylated shikimic acids, acylated ellagic acid, acylated ellagic acid analogue, and acylated hydroxybenzoic acids), active agent combinations (e.g., with a second agent that is a fatty acid) and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.

COMPOSITION FOR INHIBITING FORMATION OF SNARE COMPLEX, CONTAINING MYRICETIN DERIVATIVES

The present invention relates to a composition for inhibiting the formation of a SNARE complex, containing myricetin derivatives, and can provide a composition for inhibiting the formation of a SNARE complex, in which myricetin derivatives, which have novel structures and are obtained by the acylation of myricetin, in addition to laricitrin, combretol, and syringetin, which is one of the derivatives of myricetin, are used as a SNARE targeting prodrug, since the myricetin derivatives have an activity of inhibiting the formation of a SNARE complex in vivo. According to research results, the myricetin derivatives are considered to exhibit an effect of being bioconverted into myricetin in a cell. The myricetin derivatives lost the dark color of conventional myricetin and properties thereof were changed such that the myricetin derivatives have properties of photostability and fat solubility. Therefore, since stable form myricetin derivatives are absorbed into a cell such that an activity, possessed by normal myricetin, of inhibiting the formation of a SNARE complex are exhibited, the present invention can exhibit an excellent function as a SNARE targeting prodrug, and as a composition for inhibiting the formation of a SNARE complex, containing the same.

Preparation method of 7-O-glycosylated myricetin

The invention belongs to the technical field of chemical synthesis of drugs, and particularly relates to a preparation method of 7-O-glycosylated myricetin. The preparation method of 7-O-glycosylatedmyricetin comprises the following steps: step one, enabl

MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME

Multibiotic agents are disclosed. The multibiotic agents may contain two or more moieties linked through bonds cleavable in vivo. The bonds cleavable in vivo can be ester bonds, amide bonds, azo bonds, glycosidic bonds, carbonate linkers, or carbamate linkers. The moieties can be alcohol cores, amine cores, and/or acyls. Also disclosed are compositions containing multibiotic agents and methods of using the multibiotic agents.